MDA-231-BoM-2287 is a breast adenocarcinoma cell line established from a bone-selective metastatic derivative of the parental MDA231-TGL cell line.
This cell line is part of a panel of human breast cancer cell lines selected to metastasize to specific organs.
This cell line was established from a 51-year-old female of Caucasian ethnicity and was derived from a metastatic site of pleural effusion.
Joan Massagué, PhD, Chief Scientific Officer, Director, Sloan Kettering Institute, and Laboratory Head, Cancer Biology & Genetics Program, MSK
This cell line is jointly owned with MD Anderson and is available for licensing through an interinstitutional agreement.